Searched for
BIOPHARMACEUTICAL UNIT RESTRUCTURING
When investing for the long term, parentage matters: 6 stocks that fit the bill, 5 with an upside potential of more than 34%Confusion and fear – as well as optimism – are jostling about in the market these days. The resultant turbulence may well last till there i...- Morgan Stanley, Walmart, Pfizer and more: Full list of over 150 American companies laying off employees in JuneThe US workforce is facing significant job cuts in June 2025, following widespread layoffs in the first quarter. Reports suggest nearly 160...
- MNC pharma companies: Time to take a re-look? 8 pharma stocks, 5 with an upside of up to 34%Some time back an MNC pharma firm announced the divestment of one of its businesses in India. Another sold one of its plants. Now, with the...
- Looking at mid-caps? Keep your portfolio healthy: 5 mid-cap pharma stocks with an upside potential of up to 38%Even as the bears are running wild on the street causing across-the-board damage, there are sectors that have kept them at bay. And that’s ...
- MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...
- Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...
- Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...
- After long phase of consolidation: 4 Indian pharma stocks with upside potential of up to 41%Between 2005 to 2015, the pharma sector was one of the best performing sectors with stocks creating big wealth for the shareholders. Then c...
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...
- Finally out of the woods? 5 small and midcap pharma stocks with an upside potential of up to 23%Pharma as a sector, both in terms of business and stocks price performance has been under pressure for a very long time. Some time USFDA is...
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...
- Biocon's biosimilars progressAnalysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...
- Vyome Biosciences closes $8 million funding roundProceeds from the Series B round of funding will be used to drive the completion of critical milestones of US Food and Drug Administration ...
- Wockhardt sells nutritionals biz to AbbottWockhardt has sold its nutritionals business comprising top-selling brands Farex, Protinex, Dexolac and Nusobee, and manufacturing units at...
- Bristol-Myers to shut half of its plants in 3 yearsApart from plant shutdowns, the company plans to lay off about 4,300 employees in a broad restructuring aimed at cost savings of $1.5 b by ...
Load More
